Share chart Atossa Therapeutics, Inc.
Extended chart
Simple chart
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., биофармацевтическая компания, работающая на клинической стадии, занимается открытием и разработкой лекарств в области онкологии и инфекционных заболеваний. Ведущей программой компании является эндоксифен, активный метаболит тамоксифена, который проходит фазу II клинических испытаний для лечения и профилактики рака груди. more detailsMain settings
| IPO date | 2012-11-08 |
|---|---|
| ISIN | US04962H5063 |
| Industry | Health Care Equipment & Supplies |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | link |
| Change price per day: | 0% (0.8317) |
|---|---|
| Change price per week: | -15.44% (0.9836) |
| Change price per month: | +13.53% (0.7326) |
| Change price per 3 month: | +6.02% (0.7845) |
| Change price per half year: | -35.53% (1.29) |
| Change price per year: | -43.03% (1.46) |
| Change price per 3 year: | -16.83% (1) |
| Change price per 5 year: | -65.05% (2.38) |
| Change price per year to date: | -13.7% (0.9637) |
Grade
Underestimation
| Title | Value | Grade |
|---|---|---|
| P/S | 0 | 0 |
| P/BV | 1.71 | 8 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
|---|---|---|
| ROA, % | -29.54 | 0 |
| ROE, % | -31.39 | 0 |
| ROIC, % | -15.9 | 0 |
Dividends
| Title | Value | Grade |
|---|---|---|
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
|---|---|---|
| Debt/EBITDA | -3.2E-5 | 10 |
| Debt/Ratio | 1.3E-5 | 10 |
| Debt/Equity | 0.0695 | 10 |
Growth impulse
| Title | Value | Grade |
|---|---|---|
| Yield Revenue, % | 17.2 | 3 |
| Yield Ebitda, % | 82.16 | 9 |
| Yield EPS, % | -89.71 | 0 |
Main owners
| Institutions | Volume | Share, % |
|---|---|---|
| Morgan Stanley | 765 | 0.61 |
| Goldman Sachs Group Inc | 629 | 0.5 |
| State Street Corporation | 494 | 0.39 |
| HRT Financial LP | 291 | 0.23 |
| Vanguard Group Inc | 6 | 4.58 |
| Blackrock Inc. | 3 | 2.19 |
| Laurion Capital Management, LP | 2 | 1.77 |
| Renaissance Technologies, LLC | 1 | 1.1 |
| Geode Capital Management, LLC | 1 | 0.96 |
| Millennium Management LLC | 1 | 0.8 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Ms. Delly Behen P.H.R. | Senior Vice President of Administration & HR | N/A | |
| Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, CEO & President | 1.14M | 1951 (74 years) |
| Mr. Eric Van Zanten | Vice President of Investor & Public Relations | N/A | |
| Dr. Richard Graydon M.D., Ph.D. | Interim Chief Medical Officer | N/A | |
| Ms. Heather Rees CPA | Chief Financial Officer & Principal Accounting Officer | 1973 (52 years) |
About company
Address: United States, Seattle, 107 Spring Street - Open in google maps, Open in yandex maps
Website: https://www.atossatherapeutics.com
Website: https://www.atossatherapeutics.com
